Bibliography
- LITHELL H, HANSON L, SKOOG L et al.: The Study of Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial../. Hypertens. (2003) 21:875–886.
- SCHRADER J, LUDERS S,KUNSCHEWSKI A et al.: The ACCESS Study — evaluation of acute candesartan cilexetil in stroke survivors. Stroke (2003) 34:1699–1703.
- SKOOG I, LERNFELT B, LANDAHL Set al.: 15-year longitudinal study of blood pressure and dementia. Lancet (1996) 347:1141–1145.
- KILANDER L, NYMAN H, BOBERG M,HANSOON L, LITHELL H: Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension (1998) 31:780–786.
- DAHLOF B, DEVEREUX RB, KJELDSEN SE et al: Cardiovascular morbidity and mortality in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet (2002) 359:995–1003.
- MANN J, JULIUS S: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Blood Press. (1998) 7:176–183.
- HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE and MICROHOPE substudy. Lancet (2000) 355:253–259.
- BRENNER BM, COPPER ME, DE ZEEUW D et al.: Effects of losartan onrenal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl. I Med. (2001) 345:861–869.
- LEWIS EJ, HUNSICKER LG,CLARKE WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N EngL J. Med. (2001) 345:851–860.
- WEIMAR C, KURTH T,KRAYWINKEL K et al.: Assessment of functioning and disability after ischemic stroke. Stroke (2002) 33:2053–2059.